| Ytd | 11.85% | |
| 1y | 14.87% |
| Open | 22.12 | Prev Close | 22.22 | Low | 22.01 | High | 22.15 | Mkt Cap | 2.88B |
| Vol | 472.65K | Avg Vol | 900.38K | EPS | 2.40 | P/E | 9.20 | Forward P/E | 8.55 |
| Beta | 0.82 | Short Ratio | 8.38 | Inst. Own | 77.60% | Dividend | 0.96 | Div Yield | 4.32 |
| Ex Div Date | 08-14 | Earning | 10-28 | 50-d Avg | 23.52 | 200-d Avg | 22.44 | 1yr Est | 27.75 |
[url="]Natera, Inc.[/url] (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, t
AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improveme
[url="]Genmab A/S[/url](Nasdaq: GMAB) and AbbVie (NYSE: ABBV) announced today positive topline resul
Popular (NASDAQ: BPOP - Get Free Report) and Provident Financial Services (NYSE: PFS - Get Free Repo
ISELIN, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Provident Financial Services, Inc. (NYSE: PFS) annou
ISELIN, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Provident Bank , a leading New Jersey-based financi
More than 800 team members at the $25B+ bank have adopted MANTL to drive growth, efficiency, and bet
Highlights Assay results reported for 18 drill holes at Haib comprising 7,074m of infill and expans
TORONTO--(BUSINESS WIRE)---- $RPX.V #Canada--RPX Gold Inc. (“RPX Gold” or the “Company”) (TSXV: RPX)
Johnson and Johnson's RYBREVANTÂ (amivantamab-vmjw) plus chemotherapy delivers longest reported medi
Positive results from the DESTINY-Lung04 Phase III trial showed AstraZeneca and Daiichi Sankyo's ENH
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM)
REGN INVESTOR DEADLINE TOMORROW: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses H
Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. [url="]announced[/ur
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Ph
First OX40 agonist to demonstrate clinical benefit in a randomized study INBRX-106 plus pembrolizuma
TORONTO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Wallbridge Mining Company Limited (TSX: WM, OTCQB: WLBMF
Provident Financial (PFS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism ab
Regeneron Pharmaceuticals, Inc. (REGN) Investors: Securities Fraud Class Action Filed, Contact Hagen
Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the publication of primary analysis results
Keefe, Bruyette & Woods analyst Timothy Switzer reiterates Provident Finl Servs (NYSE:PFS) wi
Piper Sandler analyst Manuel Navas reiterates Provident Finl Servs (NYSE:PFS) with a Overweight a
Provident Finl Servs (NYSE:PFS) reported quarterly earnings of $0.60 per share which beat the analys
Raymond James analyst Steve Moss maintains Provident Finl Servs (NYSE:PFS) with a Strong Buy and
Provident Bank, a leading New Jersey-based financial institution, announced today the appointment of
Stephens & Co. analyst Matt Breese initiates coverage on Provident Finl Servs (NYSE:PFS) with
Keefe, Bruyette & Woods analyst Timothy Switzer maintains Provident Finl Servs (NYSE:PFS) wit
Provident Finl Servs (NYSE:PFS) reported quarterly earnings of $0.61 per share which beat the analys
DA Davidson analyst Jake Civiello initiates coverage on Provident Finl Servs (NYSE:PFS) with a Ne
Keefe, Bruyette & Woods analyst Timothy Switzer maintains Provident Finl Servs (NYSE:PFS) wit
Provident Finl Servs (NYSE:PFS) reported quarterly earnings of $0.64 per share which beat the analys
Options markets are pricing in post-earnings swings of up to 50% this week, with regional banks in f
Provident Bank, a leading New Jersey-based financial institution, announced today the planned retire
Provident Finl Servs (NYSE:PFS) reported quarterly earnings of $0.55 per share which beat the analys
Provident Finl Servs (NYSE:PFS) reported quarterly earnings of $0.55 per share which beat the analys
Raymond James analyst Steve Moss initiates coverage on Provident Finl Servs (NYSE:PFS) with a Str
Keefe, Bruyette & Woods analyst Timothy Switzer maintains Provident Finl Servs (NYSE:PFS) wit
Provident Finl Servs (NYSE:PFS) reported quarterly earnings of $0.49 per share which beat the analys
RBC Capital analyst Jon Arfstrom maintains Provident Finl Servs (NYSE:PFS) with a Outperform and
Provident Finl Servs (NYSE:PFS) reported quarterly earnings of $0.37 per share which missed the anal
Hovde Group analyst Feddie Strickland initiates coverage on Provident Finl Servs (NYSE:PFS) with